Table 2.

Efficacy outcomes.

Objective	Durvalumab	Durvalumab + Tremelimumab
Primary Objectives (90% CI)	n = 37	n = 38
ORR	10.8% (4.8–100%)	13.5% (6.7–100%)
PFS at 24 weeks	5.3% (1.4–100%)	13.2% (6.5–100%)
Secondary Objectives (90% CI)	n = 37	n = 38
Median PFS	7.4 weeks (7–Inf)	7.9 weeks (7–Inf)
CBR	13.5% (6.7–100%)	10.5% (4.7–100%)
DOR	24 weeks (16-Inf)	Not Reached
irRECIST Objective (90% CI)*	n = 6	n = 8
ORR	33.3% (9.3–100%)	0%

ORR, overall response rate; PFS, progression-free survival; CBR, clinical benefit rate; DOR, duration of response.

^*reported for patients who were treated beyond disease progression.